Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

This study is ongoing, but not recruiting participants.

Sponsored by:	Allergopharma Joachim Ganzer KG
Information provided by:	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00263549

Purpose

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Condition	Intervention	Phase
House Dust Mite Allergy	Biological: House dust mite Novo Helisen Depot	Phase IV

MedlinePlus related topics: Allergy

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity

Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date:	September 2002
Estimated Study Completion Date:	February 2006

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263549

Locations

Germany
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465

Sponsors and Collaborators

Allergopharma Joachim Ganzer KG

Investigators

Principal Investigator:

Annemie Narkus, M.D.

unaffiliated

More Information

Leader in specific allergy research and therapy This link exits the ClinicalTrials.gov site

Study ID Numbers:	Al0201NH
Study First Received:	December 8, 2005
Last Updated:	July 16, 2008
ClinicalTrials.gov Identifier:	NCT00263549
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:

House dust mite,
Allergy

Study placed in the following topic categories:

Hypersensitivity

ClinicalTrials.gov processed this record on January 16, 2009